Medicare beneficiaries considering a UroLift procedure for benign prostatic hyperplasia (BPH) often face questions regarding out-of-pocket expenses. Generally, Medicare Part B covers a portion of the physician’s fees, facility fees (if performed in a hospital outpatient department or ambulatory surgical center), and other related expenses. The patient’s responsibility typically involves a 20% coinsurance after meeting the Part B deductible. Supplemental insurance (Medigap) may cover some or all of this coinsurance. The exact amount can vary depending on several factors, including the physician’s charges, facility fees, and the specific Medigap policy.
Understanding potential costs associated with BPH treatment is essential for informed decision-making. While the UroLift procedure may offer certain advantages over traditional surgical interventions for BPH, such as a minimally invasive approach and quicker recovery times, accurate cost projections empower patients to navigate their financial obligations. This allows for proactive planning and potentially reduces financial stress associated with medical care.
